Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies
RTX demonstrated effectiveness in various subsets of IIMs, often leading to clinical improvement and significantly reducing the CCS dose.
Authors
- Fabio Cacciapaglia (ORCID: https://orcid.org/0000-0001-7479-4462)
- Florenzo Iannone (ORCID: https://orcid.org/0000-0003-0474-5344)
- Giuseppe Lopalco (ORCID: https://orcid.org/0000-0003-4524-9566)
- L. Coladonato (ORCID: https://orcid.org/0000-0001-8833-7289)
- Marco Fornaro (ORCID: https://orcid.org/0000-0003-1716-7432)
- Stefano Stano (ORCID: https://orcid.org/0000-0001-5207-7913)
Institutions
- Ionian University (GR)
- Precision for Medicine (United States) (US)
Publication Details
- Journal
- Reumatismo
- Published
- 2025-04-07
- DOI
- https://doi.org/10.4081/reumatismo.2025.1817
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00